Treatment of lower urinary tract symptoms/BPH with convective water vapor ablation (Rezum System) appears to provide significant improvement on two key outcome measures versus medical therapy at up to 2 years, according to a study presented at the AUA annual meeting in Boston.
Men and women with gout are at 60% greater risk for nephrolithiasis than adults without gout, according to a study looking at not only the chronic kidney condition’s incidence but also potential risk factors for first-time nephrolithiasis in people with and without gout.
The risk of erectile dysfunction is not increased with the use of a 5-alpha-reductase inhibitor compared with an alpha-blocker for the treatment of BPH.
Urologists are no longer the primary initiators of tamsulosin (Flomax) therapy in the United States, suggests an analysis of pharmaceutical claims from more than 50 private health plans.
Other pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Authors of a recent study say that long-term therapy with a 5-alpha-reductase inhibitor was associated with increased glucose, increased glycated hemoglobin, and altered lipid profiles.
Other products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more
Studies of bipolar plasma vaporization of the prostate and thulium vapoenucleation were among the other noteworthy research in BPH/LUTS presented at the AUA annual meeting in Boston.